| Dr Bobbi N Ring, MD | |
|
5645 Main St, New York Hospital Queens, Department Of Radiology, Flushing, NY 11355-5045 | |
| (718) 670-2526 | |
| Not Available |
| Full Name | Dr Bobbi N Ring |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 21 Years |
| Location | 5645 Main St, Flushing, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356509707 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 246380 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New York-presbyterian/queens | Flushing, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Main Street Radiology At Bayside Llc | 5395732671 | 45 |
| Radiology Of Main Street Pc | 5799677522 | 45 |
News Archive
Autism Speaks, the world's largest autism science and advocacy organization, is a major sponsor and scientific participant in the 2010 International Meeting for Autism Research (IMFAR).
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
Oxygen Biotherapeutics, Inc. reported today that the Data Safety Monitoring Board overseeing the company's ongoing Phase II-b trial has, based on the results of the first cohort of patients, authorized the company to move forward with the next cohort of the study. This trial is a randomized, single-dose, placebo-controlled, double-blind, dose-escalation study to evaluate the safety and tolerability of our Oxycyte® emulsion in patients with severe non-penetrating traumatic brain injury.
Turning the calendar to a new year often finds people working on their commitment to a healthy lifestyle. When it comes to losing weight, experts advise taking a longer view, beyond a New Year's resolution.
› Verified 9 days ago
| Entity Name | North Shore Hematology Oncology Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396794574 PECOS PAC ID: 1456243641 Enrollment ID: O20040324001766 |
News Archive
Autism Speaks, the world's largest autism science and advocacy organization, is a major sponsor and scientific participant in the 2010 International Meeting for Autism Research (IMFAR).
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
Oxygen Biotherapeutics, Inc. reported today that the Data Safety Monitoring Board overseeing the company's ongoing Phase II-b trial has, based on the results of the first cohort of patients, authorized the company to move forward with the next cohort of the study. This trial is a randomized, single-dose, placebo-controlled, double-blind, dose-escalation study to evaluate the safety and tolerability of our Oxycyte® emulsion in patients with severe non-penetrating traumatic brain injury.
Turning the calendar to a new year often finds people working on their commitment to a healthy lifestyle. When it comes to losing weight, experts advise taking a longer view, beyond a New Year's resolution.
› Verified 9 days ago
| Entity Name | Main Street Radiology At Bayside Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780771634 PECOS PAC ID: 5395732671 Enrollment ID: O20040428001019 |
News Archive
Autism Speaks, the world's largest autism science and advocacy organization, is a major sponsor and scientific participant in the 2010 International Meeting for Autism Research (IMFAR).
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
Oxygen Biotherapeutics, Inc. reported today that the Data Safety Monitoring Board overseeing the company's ongoing Phase II-b trial has, based on the results of the first cohort of patients, authorized the company to move forward with the next cohort of the study. This trial is a randomized, single-dose, placebo-controlled, double-blind, dose-escalation study to evaluate the safety and tolerability of our Oxycyte® emulsion in patients with severe non-penetrating traumatic brain injury.
Turning the calendar to a new year often finds people working on their commitment to a healthy lifestyle. When it comes to losing weight, experts advise taking a longer view, beyond a New Year's resolution.
› Verified 9 days ago
| Entity Name | Radiology Of Main Street Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265529101 PECOS PAC ID: 5799677522 Enrollment ID: O20040824000320 |
News Archive
Autism Speaks, the world's largest autism science and advocacy organization, is a major sponsor and scientific participant in the 2010 International Meeting for Autism Research (IMFAR).
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
Oxygen Biotherapeutics, Inc. reported today that the Data Safety Monitoring Board overseeing the company's ongoing Phase II-b trial has, based on the results of the first cohort of patients, authorized the company to move forward with the next cohort of the study. This trial is a randomized, single-dose, placebo-controlled, double-blind, dose-escalation study to evaluate the safety and tolerability of our Oxycyte® emulsion in patients with severe non-penetrating traumatic brain injury.
Turning the calendar to a new year often finds people working on their commitment to a healthy lifestyle. When it comes to losing weight, experts advise taking a longer view, beyond a New Year's resolution.
› Verified 9 days ago
| Entity Name | Sunset Park Radiology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629713672 PECOS PAC ID: 6608247291 Enrollment ID: O20230118001304 |
News Archive
Autism Speaks, the world's largest autism science and advocacy organization, is a major sponsor and scientific participant in the 2010 International Meeting for Autism Research (IMFAR).
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
Oxygen Biotherapeutics, Inc. reported today that the Data Safety Monitoring Board overseeing the company's ongoing Phase II-b trial has, based on the results of the first cohort of patients, authorized the company to move forward with the next cohort of the study. This trial is a randomized, single-dose, placebo-controlled, double-blind, dose-escalation study to evaluate the safety and tolerability of our Oxycyte® emulsion in patients with severe non-penetrating traumatic brain injury.
Turning the calendar to a new year often finds people working on their commitment to a healthy lifestyle. When it comes to losing weight, experts advise taking a longer view, beyond a New Year's resolution.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bobbi N Ring, MD 5645 Main St, New York Hospital Queens, Department Of Radiology, Flushing, NY 11355-5045 Ph: (718) 670-2526 | Dr Bobbi N Ring, MD 5645 Main St, New York Hospital Queens, Department Of Radiology, Flushing, NY 11355-5045 Ph: (718) 670-2526 |
News Archive
Autism Speaks, the world's largest autism science and advocacy organization, is a major sponsor and scientific participant in the 2010 International Meeting for Autism Research (IMFAR).
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
Oxygen Biotherapeutics, Inc. reported today that the Data Safety Monitoring Board overseeing the company's ongoing Phase II-b trial has, based on the results of the first cohort of patients, authorized the company to move forward with the next cohort of the study. This trial is a randomized, single-dose, placebo-controlled, double-blind, dose-escalation study to evaluate the safety and tolerability of our Oxycyte® emulsion in patients with severe non-penetrating traumatic brain injury.
Turning the calendar to a new year often finds people working on their commitment to a healthy lifestyle. When it comes to losing weight, experts advise taking a longer view, beyond a New Year's resolution.
› Verified 9 days ago
Kiran Chawla, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 4500 Parsons Blvd, Flushing, NY 11355 Phone: 718-670-5447 Fax: 718-670-3039 | |
Dr. David J. Axelrod, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 17660 Union Tpke Ste 130, Flushing, NY 11366 Phone: 718-820-9729 Fax: 718-820-9730 | |
Dr. Rakhi Goel, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5645 Main St, Dept Of Radiology, Flushing, NY 11355 Phone: 718-670-1888 | |
Dr. John P Derosa, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5645 Main St, Flushing, NY 11355 Phone: 718-670-1594 Fax: 718-670-1901 | |
Dr. Jeffrey C Lee, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5645 Main St, Flushing, NY 11355 Phone: 718-670-1594 Fax: 718-670-1901 | |
Lia Bartella, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 170-17 Northern Blvd, Flushing, NY 11358 Phone: 646-637-8331 Fax: 718-539-4021 | |
Dr. Han Kim, M.D. Radiology Medicare: May Accept Medicare Assignments Practice Location: 5645 Main St, Flushing, NY 11355 Phone: 718-670-1594 Fax: 718-670-1901 |